<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of acquired pure red cell aplasia (PRCA)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of acquired pure red cell aplasia (PRCA)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Causes of acquired pure red cell aplasia (PRCA)</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Primary PRCA</td> </tr> <tr> <td class="indent1">Idiopathic (autoimmune)</td> </tr> <tr> <td class="indent1">Initial presentation of MDS</td> </tr> <tr> <td class="indent1">Transient erythroblastopenia of childhood (TEC)*</td> </tr> <tr> <td class="subtitle1_single">Secondary PRCA</td> </tr> <tr> <td class="subtitle2_single">Drugs</td> </tr> <tr> <td class="indent2">Chlorpropamide</td> </tr> <tr> <td class="indent2">Erythropoietin (EPO, recombinant)</td> </tr> <tr> <td class="indent2">Immune checkpoint inhibitors (monoclonal antibodies targeting CTLA4, PD1, or PDL1)</td> </tr> <tr> <td class="indent2">Mycophenolate mofetil</td> </tr> <tr> <td class="indent2">Phenytoin</td> </tr> <tr> <td class="indent2">Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td class="indent2">Zidovudine</td> </tr> <tr> <td class="subtitle2_single">Infections</td> </tr> <tr> <td class="indent2">B19 parvovirus (transient or chronic)</td> </tr> <tr> <td class="indent2">Epstein-Barr virus</td> </tr> <tr> <td class="indent2">HIV</td> </tr> <tr> <td class="indent2">Viral hepatitis</td> </tr> <tr> <td class="subtitle2_single">Immune disorders</td> </tr> <tr> <td class="indent2">Autoimmune hemolytic anemia</td> </tr> <tr> <td class="indent2">Systemic lupus erythematosus</td> </tr> <tr> <td class="indent2">Rheumatoid arthritis</td> </tr> <tr> <td class="indent2">ABO-incompatible hematopoietic stem cell transplant</td> </tr> <tr> <td class="subtitle2_single">Neoplasms</td> </tr> <tr> <td class="indent2">Lymphoid <ul class="decimal_heading"> <li>CLL</li> <li>LGL leukemia</li> <li>Hodgkin lymphoma</li> <li>Non-Hodgkin lymphoma</li> <li>Multiple myeloma and other plasma cell disorders</li> </ul> </td> </tr> <tr> <td class="indent2">Myeloid <ul class="decimal_heading"> <li>CML</li> <li>PMF</li> </ul> </td> </tr> <tr> <td class="indent2">Other <ul class="decimal_heading"> <li>Thymoma (approximately 5% of cases)</li> <li>Cancers with anemia treated with EPO</li> </ul> </td> </tr> <tr> <td class="subtitle2_single">Pregnancy</td> </tr> </tbody></table></div><div class="graphic_lgnd">This is a partial list intended to summarize the most common causes of PRCA. Lymphocyte and plasma cell disorders are the most common underlying disorders in secondary PRCA. Additional causes (including additional drugs and viral infections) may have been reported. Refer to UpToDate for the evaluation of these disorders.</div><div class="graphic_footnotes"><p>PRCA: pure red cell aplasia; MDS: myelodysplastic syndrome; EPO: erythropoietin; CTLA-4: cytotoxic T lymphocyte associated antigen 4; PD1: programmed cell death-1; PD-L1: programmed cell death ligand 1; CLL: chronic lymphocytic leukemia; LGL: large granular lymphocyte; NHL: non-Hodgkin lymphoma; CML: chronic myelogenous leukemia; PMF: primary myelofibrosis.</p>
* TEC is an acute, self-limited PRCA seen only in childhood. It is the most common cause of PRCA in children and typically occurs in previously healthy children. The precise mechanism is unknown. Refer to the UpToDate discussion of PRCA in children for details.</div><div id="graphicVersion">Graphic 122462 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
